Jump to main content
Jump to site search

Issue 21, 2015
Previous Article Next Article

Photo-inhibition of Aβ fibrillation mediated by a newly designed fluorinated oxadiazole

Author affiliations

Abstract

Uncontrolled aggregation of amyloid beta peptide (Aβ) is the main cause of Alzheimer's disease. Therapeutic approaches to intervention in amyloid diseases include the use of small molecules able to stabilize the soluble Aβ conformation, or to redirect the amyloidogenic pathway towards non-toxic and non-fibrillar states. Fluorometric measurements revealed that 3-(4′-trifluoromethylphenyl)-5-(4′-methoxyphenyl)-1,2,4-oxadiazole, when irradiated, is able to interact with the monomeric Aβ peptide readdressing the aggregation pathway toward the formation of amorphous aggregates as evidenced by CD, AFM, and SAXS measurements. We hypothesize that this compound, under radiation, forms a reactive intermediate that sticks on the Aβ peptide by interfering with its fibrillation process. Cytotoxicity assays performed on LAN5 neuroblastoma cells suggest that the presence of oxadiazole reduces the toxicity of Aβ. This finding might be the start of innovative therapies against Alzheimer's disease.

Graphical abstract: Photo-inhibition of Aβ fibrillation mediated by a newly designed fluorinated oxadiazole

Back to tab navigation

Supplementary files

Article information


Submitted
31 Oct 2014
Accepted
27 Jan 2015
First published
29 Jan 2015

RSC Adv., 2015,5, 16540-16548
Article type
Paper
Author version available

Photo-inhibition of Aβ fibrillation mediated by a newly designed fluorinated oxadiazole

M. R. Mangione, A. Palumbo Piccionello, C. Marino, M. G. Ortore, P. Picone, S. Vilasi, M. Di Carlo, S. Buscemi, D. Bulone and P. L. San Biagio, RSC Adv., 2015, 5, 16540
DOI: 10.1039/C4RA13556C

Social activity

Search articles by author

Spotlight

Advertisements